TLSI

TriSalus Life Sciences, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website risaluslifesci.com
Employees(FY) 106
ISIN US89680M1018

Performance

+3.68%

+7.86%

+34.42%

-7.12%

+6.79%

YTD

-40.82%

Profile

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Advanced Technical Analysis

Technical Analysis of TLSI 2025-01-31

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83 and a Technical Score of 82, indicating robust upward momentum. However, the Oscillators Score of 50 suggests a neutral stance, implying that while the overall trend is positive, there may be some consolidation or indecision in the short term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TLSI

Stock Rank

Recent News & Updates

2025-02-02 19:00
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed(Businesswire)
2025-01-22 19:00
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call(Businesswire)
2025-01-09 19:30
TriSalus Life Sciences announces publication of pre-clinical data(Yahoo Finance)
2025-01-08 19:00
TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System(Businesswire)
2025-01-07 19:00
TriSalus Announces Leadership Changes(Businesswire)
2024-11-13 19:00
TriSalus Reports Q3 2024 Financial Results and Provides Business Update(Businesswire)
2024-11-12 18:27
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For(Yahoo Finance)
2024-11-10 18:00
TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer(Businesswire)
2024-11-06 18:00
TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment(Businesswire)
2024-10-30 20:00
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call(Businesswire)
2024-10-14 04:05
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit(Businesswire)
2024-09-25 19:00
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board(Businesswire)
2024-09-22 19:00
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System(Businesswire)
2024-09-13 13:52
TriSalus Life Sciences Inc (TLSI) CEO Buys Shares(Yahoo Finance)
2024-08-14 20:00
TriSalus Reports Q2 2024 Financial Results and Business Update(Businesswire)
2024-07-31 19:00
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call(Businesswire)
2024-07-01 04:00
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation(Businesswire)
2024-06-26 05:45
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants(Businesswire)
2024-06-02 19:00
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting(Businesswire)
2024-05-23 18:05
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants(Businesswire)
2024-05-15 00:53
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-14 20:00
TriSalus Reports Q1 2024 Financial Results and Business Update(Businesswire)
2024-05-06 19:00
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors(Businesswire)
2024-05-06 04:58
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call(Businesswire)
2024-04-30 04:35
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives(Businesswire)
2024-04-01 00:53
TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023(Investorplace)
2024-03-31 21:33
TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ...(Yahoo Finance)
2024-03-31 20:00
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update(Businesswire)
2024-03-25 20:00
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting(Businesswire)
2024-03-20 20:00
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting(Businesswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.